---
schema_version: "secwatch.filing_event.v1"
accession: "0001420720-24-000002"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:08:55.304702+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "low"
source: SEC EDGAR
---

# iBio files updated corporate presentation; no financial details in filing

## Summary
- Company furnished a new investor presentation dated January 2024 as Exhibit 99.1.
- Presentation title emphasizes precision antibody therapeutics and machine learning.
- No specific financial metrics, guidance, or operational updates disclosed in the filing text.

## SEC filing metadata
- accession: 0001420720-24-000002
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000002/0001420720-24-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000142072024000002/ibio-20240108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001420720-24-000002
- JSON: https://secwatch.observer/filing/0001420720-24-000002.json
- Plain text: https://secwatch.observer/filing/0001420720-24-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.